Original Research
Monday, November 13, 2023
01:00 PM–02:30 PM
Abstract
Introduction:
Adverse events (AEs) detected in Twitter and the FDA Adverse Event Reporting System (FAERS) can provide valuable insights into patients’ experiences and perceptions of the oral hypoglycemic agents including SGLT2 and DPP4 inhibitors.
Research Question or Hypothesis: This study aimed to compare AEs detected in Twitter with those in FAERS to identify the adverse events of SGLT2 inhibitor and DPP4 inhibitor.
Study Design: Cross-sectional study
Methods: We collected AE data through Twitter and the FAERS during 2017-2021. Tweets were annotated to indicate the presence of relevant sentence to extract. Subsequently, manual labeling was performed to identify AE terms. The data obtained from both data source was classified as MedDRA’s System Organ Class (SOC). Renal and urinary disorders was defined as the index comparator with a value of 1.0. A relative frequency of an AE compared with the index comparator was obtained.
Results: A total of 19,491 tweets were manually annotated. In addition, 34,202 SGLT2-Inhibitors and 3,687 DPP4-Inhibitors cases of AEs were collected in FAERS. It was similar for SOC categories with high frequencies of AE cases for both SGLT2 inhibitors and DPP4 inhibitors. The largest discrepancy between the two datasets for DPP4 inhibitors was observed in the “Neoplasms benign, malignant, and unspecified” category. It ranked 15th in the FAERS frequency, while 3rd in the frequency of Twitter data, indicating a significant difference. For the SGLT2 inhibitor, the most obvious difference was in the category of “Surgical and medical procedural combinations”. Comparing the Index calculated based on the percentage of “Renal and Urinary disorders”, FAERS showed a difference of 0.48, while tweets showed 3.49 which is more than seven times.
Conclusion: Despite the differences in the quantity and types of the AEs between the two sources, we were able to identify which AEs patients are concerned and worried about among clinically significant side effects.
Presenting Author
Yun-Kyoung Song Ph.DCollege of Pharmacy, Seoul National University
Authors
Yun Jeong Kim BS
Daegu Catholic University
Joo Han Lee BS
Daegu Catholic University
Se Hun Oh BS
Daegu Catholic University
Dong Young Park BS
Daegu Catholic University
Yeon Su Choi BS
Daegu Catholic University